We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lilly Prevails in Patent Challenge to Alimta Vitamin Regimen
Lilly Prevails in Patent Challenge to Alimta Vitamin Regimen
It would be obvious to treat a patient with folic acid before administering Lilly’s antifoliate chemotherapy drug Alimta (pemetrexed) to reduce Alimta’s toxic effects, the PTO’s Patent Trial and Appeals Board ruled in a challenge to Lilly.